Announcement • Aug 13

+ 1 more update

Citius Oncology, Inc. completed the acquisition of TenX Keane Acquisition (NasdaqGM:TENK) from 10XYZ Holdings LP, Hudson Bay Capital Management LP, Wolverine Asset Management, LLC, Mizuho Financial Group, Inc. and others in a reverse merger transaction.

Citius Oncology, Inc. signed the letter of intent to acquire TenX Keane Acquisition (NasdaqGM:TENK) from 10XYZ Holdings LP, Hudson Bay Capital Management LP, Wolverine Asset Management, LLC, Mizuho Financial Group, Inc. and others in a reverse merger transaction on May 16, 2023. Citius Oncology, Inc. entered into an agreement and plan of merger to acquire TenX Keane Acquisition from 10XYZ Holdings LP and others for approximately $730 million in a reverse merger transaction on October 23, 2023. Combined public company will be named Citius Oncology, Inc. Upon closing, pursuant to the terms of the merger agreement, Citius Pharmaceuticals, Inc. ("Citius Pharma") would receive 67.5 million shares in the combined company and retain majority ownership of approximately 90% and TenX expected to own approximately 10% of Citius Oncology. Myron Holubiak will serve as Executive Vice Chairman of the Citius Oncology Board of Directors. In case of termination under certain circumstances, Citius Pharma to pay a $5,000,000 Termination Fee to TenX. Transaction is subject to approval by stockholders of TenX; all requisite regulatory approvals, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder, have been obtained and remain in full force and effect and all statutory waiting periods in respect thereof have expired or been terminated; the registration statement and proxy statement/prospectus becoming effective under the Securities Act of 1933, as amended; TenX having at least $5,000,001 in net tangible assets and other customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both companies. Citius Pharma, as the sole holder of Citius Oncology common stock, has approved the transaction. TenX shareholders approved the transaction on an extraordinary general meeting on August 2, 2024. Transaction is expected to close in the first half of 2024. As of May 17, 2024, the expected closing date was extended from May 18, 2024 to June 18, 2024. As per updated filing, the expected closing date was extended from June 18, 2024 to July 18, 2024. As of August 5, 2024, the transaction is expected to close in the coming weeks. Maxim Group LLC is acting as exclusive financial advisor to Citius Pharma and Newbridge Securities Corporation is acting as exclusive financial advisor to TenX. David Creekman and Alec Donaldson of Wyrick Robbins Yates & Ponton LLP acting as legal advisors to Citius Pharma. Tammara Fort and Samara Thomas of The Crone Law Group P.C. acting as legal advisors to TenX. American Stock Transfer & Trust Company, LLC is acting as exchange agent for TenX. As part of the merger, TenX will issue $500,000 in shares at $10.00 per share (50,000 shares) to Newbridge Securities Corporation (“Newbridge”) as payment of its financial advisory fee. D.F. King & Co., Inc acted as proxy solicitor to TenX and TenX has agreed to pay a fee of $25,000, plus fees and expenses. Revere Securities acted as financial advisor and fairness opinion provider to TenX. Maxim Group LLC acted as due diligence provider to Citius Pharma. Marcum LLP acted as due diligence provider to TenX. Citius Oncology, Inc. completed the acquisition of TenX Keane Acquisition (NasdaqGM:TENK) from 10XYZ Holdings LP, Hudson Bay Capital Management LP, Wolverine Asset Management, LLC, Mizuho Financial Group, Inc. and others in a reverse merger transaction on August 12, 2024. Shares of Citius Oncology expected to begin trading on Nasdaq on August 13, 2024 under ticker CTOR. Citius Pharma holds approximately 90% of the newly public company. Citius Oncology will operate under a shared services agreement with Citius Pharma for the services of several key members of the Citius Pharma team, led by Leonard Mazur, Chief Executive Officer, Jaime Bartushak, Chief Financial Officer and Dr. Myron Czuczman, Chief Medical Officer.

TenX Keane Acquisition Stock Price

TENK Share Price Performance

TENK Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

TenX Keane Acquisition Key Details

About TENK

Recent TENK News & Updates

Citius Oncology, Inc. completed the acquisition of TenX Keane Acquisition (NasdaqGM:TENK) from 10XYZ Holdings LP, Hudson Bay Capital Management LP, Wolverine Asset Management, LLC, Mizuho Financial Group, Inc. and others in a reverse merger transaction.

TenX Keane Acquisition announced that it has received $0.066667 million in funding

Recent updates

TenX Keane Acquisition Competitors

Compass Diversified

Associated Capital Group

Hudson Executive Investment III

World Acceptance